Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BeiGene Ltd ( (HK:6160) ) has issued an update.
BeOne Medicines Ltd., a Swiss corporation, announced it will release its unaudited financial results for the second quarter of 2025 on August 6, 2025, following the trading hours of the Hong Kong Stock Exchange. The results, prepared in accordance with U.S. GAAP, will be reviewed by the company’s audit committee. A conference call with management will follow the release, and an archived webcast will be available on the company’s website. The interim results will also be announced in compliance with the HK Listing Rules by August 29, 2025, including a reconciliation from U.S. GAAP to IFRS.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,572,063
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$245.7B
For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.